61 related articles for article (PubMed ID: 20656484)
1. Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation.
Fujii S; Ohsawa F; Yamada S; Shinozaki R; Fukai R; Makishima M; Enomoto S; Tai A; Kakuta H
Bioorg Med Chem Lett; 2010 Sep; 20(17):5139-42. PubMed ID: 20656484
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.
Shimizu M; Moriwaki H
PPAR Res; 2008; 2008():181047. PubMed ID: 18528526
[TBL] [Abstract][Full Text] [Related]
3. Retinoid X Receptor agonists as selective modulators of the immune system for the treatment of cancer.
Leal AS; Hung PY; Chowdhury AS; Liby KT
Pharmacol Ther; 2023 Dec; 252():108561. PubMed ID: 37952906
[TBL] [Abstract][Full Text] [Related]
4. Structural Modification of the Natural Product Valerenic Acid Tunes RXR Homodimer Agonism.
Zaienne D; Isigkeit L; Marschner JA; Duensing-Kropp S; Höfner G; Merk D
ChemMedChem; 2023 Nov; 18(21):e202300404. PubMed ID: 37697963
[TBL] [Abstract][Full Text] [Related]
5. Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats.
Wang S; Wen P; Wood S
F1000Res; 2016; 5():138. PubMed ID: 27239272
[TBL] [Abstract][Full Text] [Related]
6. Structural Fusion of Natural and Synthetic Ligand Features Boosts RXR Agonist Potency.
Adouvi G; Nawa F; Ballarotto M; Rüger LA; Knümann L; Kasch T; Arifi S; Schubert-Zsilavecz M; Willems S; Marschner JA; Pabel J; Merk D
J Med Chem; 2023 Dec; 66(24):16762-16771. PubMed ID: 38064686
[TBL] [Abstract][Full Text] [Related]
7. Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties.
Lewandowski M; Carmina M; Knümann L; Sai M; Willems S; Kasch T; Pollinger J; Knapp S; Marschner JA; Chaikuad A; Merk D
J Med Chem; 2024 Feb; 67(3):2152-2164. PubMed ID: 38237049
[TBL] [Abstract][Full Text] [Related]
8. Solution Structures of PPARγ2/RXRα Complexes.
Osz J; Pethoukhov MV; Sirigu S; Svergun DI; Moras D; Rochel N
PPAR Res; 2012; 2012():701412. PubMed ID: 23319938
[TBL] [Abstract][Full Text] [Related]
9. Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN.
Kawasaki M; Motoyama T; Yamada S; Watanabe M; Fujihara M; Kambe A; Nakano S; Kakuta H; Ito S
ACS Med Chem Lett; 2023 Mar; 14(3):291-296. PubMed ID: 36923911
[TBL] [Abstract][Full Text] [Related]
10. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
[TBL] [Abstract][Full Text] [Related]
11. Increased Molecular Flexibility Widens the Gap between
Watanabe M; Nakamura-Nakayama M; Fujihara M; Kawasaki M; Nakano S; Kakuta H
ACS Med Chem Lett; 2022 Feb; 13(2):211-217. PubMed ID: 35178177
[TBL] [Abstract][Full Text] [Related]
12. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
[TBL] [Abstract][Full Text] [Related]
13. Creation of Fluorescent RXR Antagonists Based on CBTF-EE and Application to a Fluorescence Polarization Binding Assay.
Takioku M; Takamura Y; Fujihara M; Watanabe M; Yamada S; Kawasaki M; Ito S; Nakano S; Kakuta H
ACS Med Chem Lett; 2021 Jun; 12(6):1024-1029. PubMed ID: 34141088
[TBL] [Abstract][Full Text] [Related]
14. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Moerland JA; Zhang D; Reich LA; Carapellucci S; Lockwood B; Leal AS; Krieger-Burke T; Aleiwi B; Ellsworth E; Liby KT
Sci Rep; 2020 Dec; 10(1):22244. PubMed ID: 33335263
[TBL] [Abstract][Full Text] [Related]
15. A review of the molecular design and biological activities of RXR agonists.
de Almeida NR; Conda-Sheridan M
Med Res Rev; 2019 Jul; 39(4):1372-1397. PubMed ID: 30941786
[TBL] [Abstract][Full Text] [Related]
16. Scaffold-Hopping from Synthetic Drugs by Holistic Molecular Representation.
Grisoni F; Merk D; Byrne R; Schneider G
Sci Rep; 2018 Nov; 8(1):16469. PubMed ID: 30405170
[TBL] [Abstract][Full Text] [Related]
17. Retinoid X Receptor Antagonists.
Watanabe M; Kakuta H
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103423
[TBL] [Abstract][Full Text] [Related]
18. RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
Kakuta H; Yakushiji N; Shinozaki R; Ohsawa F; Yamada S; Ohta Y; Kawata K; Nakayama M; Hagaya M; Fujiwara C; Makishima M; Uno S; Tai A; Maehara A; Nakayama M; Oohashi T; Yasui H; Yoshikawa Y
ACS Med Chem Lett; 2012 May; 3(5):427-32. PubMed ID: 24900488
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Potent Retinoid X Receptor Antagonist Structurally Closely Related to RXR Agonist NEt-3IB.
Nakayama M; Yamada S; Ohsawa F; Ohta Y; Kawata K; Makishima M; Kakuta H
ACS Med Chem Lett; 2011 Dec; 2(12):896-900. PubMed ID: 24900278
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
